Compare GRFS & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | INSP |
|---|---|---|
| Founded | 1940 | 2007 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 3.8B |
| IPO Year | 2006 | 2018 |
| Metric | GRFS | INSP |
|---|---|---|
| Price | $9.00 | $115.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $10.15 | ★ $132.27 |
| AVG Volume (30 Days) | 563.8K | ★ 1.8M |
| Earning Date | 01-01-0001 | 11-03-2025 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | 0.64 | ★ 1.48 |
| Revenue | ★ $8,821,017,248.00 | $882,622,000.00 |
| Revenue This Year | $5.46 | $14.97 |
| Revenue Next Year | $5.60 | $11.81 |
| P/E Ratio | ★ $17.68 | $88.53 |
| Revenue Growth | 7.31 | ★ 16.81 |
| 52 Week Low | $6.19 | $70.77 |
| 52 Week High | $11.14 | $216.01 |
| Indicator | GRFS | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 49.30 |
| Support Level | $8.81 | $132.39 |
| Resistance Level | $9.22 | $147.03 |
| Average True Range (ATR) | 0.25 | 8.11 |
| MACD | 0.06 | -2.66 |
| Stochastic Oscillator | 84.81 | 7.40 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.